130
Participants
Start Date
November 20, 2018
Primary Completion Date
May 13, 2020
Study Completion Date
July 9, 2022
3.2 mg intranasal carbetocin
three times per day with meals
9.6 mg intranasal carbetocin
three times per day with meals
placebo
three times per day with meals
Queensland Children's Hospital, South Brisbane
Children's Hospital of Philadelphia, Philadelphia
Children's National, Washington D.C.
University of Florida, Gainesville
University of Alabama at Birmingham, Birmingham
Vanderbilt University School of Medicine, Nashville
Nationwide Children's Hospital, Columbus
Children's Hospitals and Clinics of Minnesota, Saint Paul
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Cardinal Glennon Children's Medical Center, St Louis
Kansas University Medical Center, Kansas City
University of Oklahoma Health Sciences Center, Tulsa
Texas Children's Hospital, Houston
Children's Hospital of San Antonio, San Antonio
Children's Hospital Colorado, Aurora
University of Utah, Salt Lake City
Phoenix Children's Hospital, Phoenix
Children's Hospital of Los Angeles (USC), Los Angeles
Rady Children's Hospital San Diego, San Diego
University of Harvard Boston Children's Hospital, Boston
University of Alberta, Edmonton
British Columbia Children's Hospital, Vancouver
Toronto Hospital for Sick Kids, Toronto
CHU Ste Justine, Montreal
Lead Sponsor
Levo Therapeutics, Inc.
INDUSTRY